Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study

Puntos clave

• To compare clinical outcomes of FTD-TPI combined with bevacizumab versus FTD-TPI or regorafenib in metastatic colorectal cancer.
• Analyzed a large multicenter cohort of mCRC patients.
• Compared progression-free survival (PFS) and disease control rate (DCR) among treatment groups.
• Examined molecular subgroup responses, particularly KRAS mutations.
• FTD-TPI plus bevacizumab showed improved PFS compared to FTD-TPI alone.
• DCR was significantly higher with FTD-TPI plus bevacizumab than with regorafenib.
• Benefits were consistent across various molecular subgroups, including those with KRAS mutations.

Resumen